File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Immunomodulatory agents against IgA nephropathy

TitleImmunomodulatory agents against IgA nephropathy
Authors
Issue Date2011
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/ADORL
Citation
Advances In Oto-Rhino-Laryngology, 2011, v. 72, p. 45-49 How to Cite?
AbstractSynthesis of aberrant IgA molecules as the key pathogenetic mechanism of immunoglobulin A nephropathy (IgAN) apparently forms a potential scientific rationale for applying immunomodulatory agents in the treatment of IgAN. There is evidence that corticosteroids can steadily reduce proteinuria and slow down renal progression. Evidence that pulse steroid plus intravenous or oral cyclophosphamide can retard the rate of progression of advanced IgAN was provided by several groups worldwide. Cyclosporin is generally not used to treat IgAN. The efficacy of azathioprine is equivocal. Mycophenolate mofetil reduces proteinuria by up to 30% and favorably impacts renal survival in Chinese patients with mild histologic lesions, but these results were not achieved in Caucasians with more advanced disease. In conclusion, the choice of immunomodulatory therapy remains controversial. We advocate the use of immunomodulatory agents as an adjunctive therapy in patients with proteinuria > 1 g/day despite achieving target blood pressure with full renin-angiotensin blockade. More aggressive therapy should be reserved for patients with nephrotic-range proteinuria, crescentic lesions and/or rapidly progressive renal failure. Copyright © 2011 S. Karger AG, Basel.
Persistent Identifierhttp://hdl.handle.net/10722/142397
ISSN
2015 SCImago Journal Rankings: 0.398
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, SCen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2011-10-28T02:45:05Z-
dc.date.available2011-10-28T02:45:05Z-
dc.date.issued2011en_HK
dc.identifier.citationAdvances In Oto-Rhino-Laryngology, 2011, v. 72, p. 45-49en_HK
dc.identifier.issn0065-3071en_HK
dc.identifier.urihttp://hdl.handle.net/10722/142397-
dc.description.abstractSynthesis of aberrant IgA molecules as the key pathogenetic mechanism of immunoglobulin A nephropathy (IgAN) apparently forms a potential scientific rationale for applying immunomodulatory agents in the treatment of IgAN. There is evidence that corticosteroids can steadily reduce proteinuria and slow down renal progression. Evidence that pulse steroid plus intravenous or oral cyclophosphamide can retard the rate of progression of advanced IgAN was provided by several groups worldwide. Cyclosporin is generally not used to treat IgAN. The efficacy of azathioprine is equivocal. Mycophenolate mofetil reduces proteinuria by up to 30% and favorably impacts renal survival in Chinese patients with mild histologic lesions, but these results were not achieved in Caucasians with more advanced disease. In conclusion, the choice of immunomodulatory therapy remains controversial. We advocate the use of immunomodulatory agents as an adjunctive therapy in patients with proteinuria > 1 g/day despite achieving target blood pressure with full renin-angiotensin blockade. More aggressive therapy should be reserved for patients with nephrotic-range proteinuria, crescentic lesions and/or rapidly progressive renal failure. Copyright © 2011 S. Karger AG, Basel.en_HK
dc.languageengen_US
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/ADORLen_HK
dc.relation.ispartofAdvances in Oto-Rhino-Laryngologyen_HK
dc.subject.meshGlomerulonephritis, IGA - drug therapy - immunologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunity, Innate - drug effectsen_HK
dc.subject.meshImmunoglobulin A - drug effects - immunologyen_HK
dc.subject.meshImmunologic Factors - therapeutic useen_HK
dc.subject.meshImmunomodulation - drug effectsen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleImmunomodulatory agents against IgA nephropathyen_HK
dc.typeArticleen_HK
dc.identifier.emailTang, SC: scwtang@hku.hken_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityTang, SC=rp00480en_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000324602en_HK
dc.identifier.pmid21865687-
dc.identifier.scopuseid_2-s2.0-80052489907en_HK
dc.identifier.hkuros197040en_US
dc.identifier.hkuros203715-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80052489907&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume72en_HK
dc.identifier.spage45en_HK
dc.identifier.epage49en_HK
dc.identifier.isiWOS:000302382800009-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridTang, SC=7403437082en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats